Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer
Conditions
Brief summary
This phase II trial is studying how well cediranib maleate works in treating patients with persistent, recurrent, or refractory advanced ovarian epithelial, peritoneal cavity, or fallopian tube cancer. Cediranib maleate may stop the growth of tumor cells by blocking blood flow to the tumor and by blocking some of the enzymes needed for cell growth.
Detailed description
PRIMARY OBJECTIVES: I. Objective tumor response rate (complete plus partial response plus stable disease \> 16 weeks as defined by the Response Evaluation Criteria in Solid Tumors \[RECIST\] criteria) in women with recurrent or refractory advanced ovarian or primary peritoneal cancer. SECONDARY OBJECTIVES: I. Time to disease progression, median survival time, and duration of overall cancer antigen (CA)-125 response. OUTLINE: Patients receive cediranib maleate orally (PO) once daily (QD) every 4 weeks in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up at 4 weeks and then every 3 months thereafter.
Interventions
DRUGcediranib maleate
30mg given PO, daily
OTHERlaboratory biomarker analysis
Correlative studies
Sponsors
National Cancer Institute (NCI)
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
19 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients must have histologically or cytologically confirmed epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer that has recurred or is refractory to initial therapy; patients must have received platinum-based chemotherapy before entry into this protocol * Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as \> 20 mm with conventional techniques or as \> 10 mm with spiral computed tomography (CT) scan OR patients must have evidence of progression based on an elevated CA-125 (defined as a value of \> 2 x upper limit of normal \[ULN\] documented on two separate determinations made \> 2 weeks apart) if the physical exam is normal and CT scan of the chest/abdomen/pelvis, has a disease volume \< 1 cm in maximum diameter * Patients may have received no more than one prior chemotherapy regimen (i.e. initial first-line chemotherapy only) * Life expectancy of greater than 12 weeks * Eastern Cooperative Oncology Group (ECOG) performance status =\< 2 (Karnofsky \>= 60%) * Leukocytes \>= 3,000/mcL * Absolute neutrophil count \>= 1,500/mcL * Platelets \>= 100,000/mcL * Hemoglobin \>= 8 g/dL * Total bilirubin within normal institutional limits * Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \[SGPT\]) =\< 2.5 × institutional upper limit of normal * Creatinine within normal institutional limits OR creatinine clearance \>= 60 mL/min/1.73 m\^2 for patients with creatinine levels above institutional normal * Women of child-bearing potential must have a negative pregnancy test prior to study entry; women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately * Ability to understand and the willingness to sign a written informed consent document
Exclusion criteria
* Patients who have had chemotherapy, radiotherapy, or major surgery within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier * Patients with borderline tumors or tumors of low malignant potential * Patients with current bowel obstruction * Patients may not be receiving any other investigational agents nor have participated in an investigational trial within the past 30 days * Patients with known brain metastases should be excluded from this clinical trial * History of allergic reactions attributed to compounds of similar chemical or biologic composition to AZD2171 (cediranib maleate) * Mean corrected QT (QTc) \> 470 msec (with Bazett's correction) in screening electrocardiogram or history of familial long QT syndrome * Greater than +1 proteinuria on two consecutive dipsticks taken no less than 1 week apart * Uncontrolled intercurrent illness including, but not limited to hypertension, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements * Pregnant women are excluded from this study, breastfeeding should be discontinued if the mother is treated with AZD2171 * Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible * Any significant abnormality noted in the electrocardiogram (ECG) within 14 days of treatment * A New York Heart Association classification of III or IV (NOTE: patients classified as class II controlled with treatment may continue with increase monitoring) * Conditions requiring concurrent use of drugs or biologics with proarrythmic potential; these drugs are prohibited during studies with AZD2171
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Response Benefit (Complete Response or Partial Response or Stable Disease) Based on the RECIST/Rustin Criteria | After 16 weeks | Per Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>= 30% decrease in the sum of the longest diameter of target lesions; Overall Response(OR) = CR+PR |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Time to Disease Progression | Up to 4 years | Standard descriptive statistics, such as the mean, median, range and proportion, will be used to summarize the patient sample and to estimate parameters of interest. Ninety-five percent confidence intervals will be provided for estimates of interest where possible. |
| Overall Survival (OS) (Discontinued as of 4/25/2014) | From date of radomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 32 months. | The Kaplan-Meier method will be used to estimate OS. Standard descriptive statistics, such as the mean, median, range and proportion, will be used to summarize the patient sample and to estimate parameters of interest. Ninety-five percent confidence intervals will be provided for estimates of interest where possible. |
| Progression-free Survival (PFS) | Time from start of treatment to time of progression, assessed up to 6 months | The Kaplan-Meier method will be used to estimate PFS. Standard descriptive statistics, such as the mean, median, range and proportion, will be used to summarize the patient sample and to estimate parameters of interest. Ninety-five percent confidence intervals will be provided for estimates of interest where possible. Progression is defined using Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion or the appearance of new lesions. |
| Duration of Overall CA-125 Response | Up to 4 years | Confirmed response on CA125 - defined as reduction in level of pre-treatment sample by \> 50%. |
| Incidence of Toxicity Graded According to National Cancer Institution Common Terminology Criteria for Adverse Events Version 3.0 | Up to 4 years | — |
Countries
Canada, United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Treatment (Cediranib Maleate) Patients receive cediranib maleate PO QD every 4 weeks in the absence of disease progression or unacceptable toxicity.
cediranib maleate: Given PO
laboratory biomarker analysis: Correlative studies | 74 |
| Total | 74 |
Baseline characteristics
| Characteristic | Treatment (Cediranib Maleate) |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 19 Participants |
| Age, Categorical Between 18 and 65 years | 55 Participants |
| Age, Continuous | 58 years |
| Region of Enrollment Canada | 52 participants |
| Region of Enrollment United States | 22 participants |
| Sex: Female, Male Female | 74 Participants |
| Sex: Female, Male Male | 0 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 47 / 74 |
| serious Total, serious adverse events | 5 / 74 |
Outcome results
Primary
Response Benefit (Complete Response or Partial Response or Stable Disease) Based on the RECIST/Rustin Criteria
Per Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>= 30% decrease in the sum of the longest diameter of target lesions; Overall Response(OR) = CR+PR
Time frame: After 16 weeks
Population: Total # of Patients 74 PL-S (platinum sensitive) 39 patients PL-R (platinum resistant) 35 patients Confirmed PR PL-S group 9/39 patients Confirmed PR PL-R group 0/35 patients
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Treatment (Cediranib Maleate) | Response Benefit (Complete Response or Partial Response or Stable Disease) Based on the RECIST/Rustin Criteria | Platinum sensitive participants | 9 participants |
| Treatment (Cediranib Maleate) | Response Benefit (Complete Response or Partial Response or Stable Disease) Based on the RECIST/Rustin Criteria | Platinum resistant participants | 0 participants |
Secondary
Duration of Overall CA-125 Response
Confirmed response on CA125 - defined as reduction in level of pre-treatment sample by \> 50%.
Time frame: Up to 4 years
Population: 1 confirmed PR observed in PS group. Response will be defined as reduction in level of pre-treatment sample by \> 50%.~0 confirmed PR observed in PR group.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Treatment (Cediranib Maleate) | Duration of Overall CA-125 Response | Platinum sensitive participants | 108 weeks |
Secondary
Incidence of Toxicity Graded According to National Cancer Institution Common Terminology Criteria for Adverse Events Version 3.0
Time frame: Up to 4 years
Population: Data were not collected.
Secondary
Overall Survival (OS) (Discontinued as of 4/25/2014)
The Kaplan-Meier method will be used to estimate OS. Standard descriptive statistics, such as the mean, median, range and proportion, will be used to summarize the patient sample and to estimate parameters of interest. Ninety-five percent confidence intervals will be provided for estimates of interest where possible.
Time frame: From date of radomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 32 months.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Treatment (Cediranib Maleate) | Overall Survival (OS) (Discontinued as of 4/25/2014) | 18.9 months |
Secondary
Progression-free Survival (PFS)
The Kaplan-Meier method will be used to estimate PFS. Standard descriptive statistics, such as the mean, median, range and proportion, will be used to summarize the patient sample and to estimate parameters of interest. Ninety-five percent confidence intervals will be provided for estimates of interest where possible. Progression is defined using Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion or the appearance of new lesions.
Time frame: Time from start of treatment to time of progression, assessed up to 6 months
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Treatment (Cediranib Maleate) | Progression-free Survival (PFS) | 4.9 months |
Secondary
Time to Disease Progression
Standard descriptive statistics, such as the mean, median, range and proportion, will be used to summarize the patient sample and to estimate parameters of interest. Ninety-five percent confidence intervals will be provided for estimates of interest where possible.
Time frame: Up to 4 years
Population: Platinum sensitive cohort
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Treatment (Cediranib Maleate) | Time to Disease Progression | Platinum Sensitive Participants | 7.2 months |
| Treatment (Cediranib Maleate) | Time to Disease Progression | Platinum Resistant Participants | 3.7 months |